<DOC>
	<DOC>NCT01440686</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of HL-032 after oral administration in healthy male volunteers.</brief_summary>
	<brief_title>Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Dwarfism, Pituitary</mesh_term>
	<criteria>Healthy male subjects Age(yr)between 19 and 50 Signed written informed consent Known hypersensitivity to Octreotide or hGH(human growth hormone) History of Cardiovascular, Respiratory, Renal/Genitourinary, Gastrointestinal, Neurological/Psychic, cancer Alcoholic, smokers or drug abusers Other conditions which in the opinion of the investigator preclude enrollment into the study</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Safety</keyword>
	<keyword>Male</keyword>
</DOC>